area could also suggest a hormonal risk factor
(Badaoui et al., 2016). Finally, commensal bacteria
may play an essential role as alloantigens in the
pathophysiology of DCS (Badaoui et al., 2016). The
loss of immune tolerance to these alloantigens may
lead to an inflammatory reaction (Badaoui et al.,
2016; Scheinfeld, 2014). To the best of authors’
knowledge, this is the third case of DCS in an
Indonesian man. Although unpublished, Sirait (2015)
reported the occurrence of DCS associated with
hidradenitis suppurativa in 2015. Rahman et al.
(2017) then reported a case of follicular occlusion
tetrad in 2017. This patient is a 43-year-old
Indonesian man with straight hairs and no associated
mechanical trauma. There was also no familial
history with the same complaints. The signs and
symptoms of patient reported in this report are well
suited with DCS despite the lack of associated
predisposing factors except male gender. Other
explanations supporting the diagnosis of DCS are
listed below:
1. Anamnesis: lumps that discharged purulent
material on the predilection areas. History of
severe acne during his adolescence to early
adulthood.
2. Physical examination: observed subcutaneous
nodules, abscesses, and sinuses that
discharged purulent exudate.
3. Trichoscopic examination: yellowish and
whitish area lacking of follicular openings.
These were consistent with trichoscopic
findings explained by Laccarubba et al (2017).
4. Histopathological examination: follicular
occlusion, dilatation, and rupture with mixed
inflammatory infiltrates, mainly neutrophils.
Multiple hair shaft fragments are evident in
pilonidal cyst (Calonje et al., 2012). This
feature is not observed, so that the
histopathology is more suited with DCS than
pilonidal cyst.
DCS must be distinguished with other diseases
involving scalp (Vasant et al., 2014). The tendency of
DCS to cause fluctuating nodules and sinus tracts
helps to distinguish it from acne keloidalis nuchae
(AKN) (Vasant et al., 2014). Folliculitis decalvans,
another differential diagnosis, is characterized by
tufted folliculitis, in which multiple hair tufts emerge
from dilated follicular orifices (Vasant et al., 2014).
Various therapeutic strategies were reported
successful in treating DCS, such as systemic
antibiotics (minocycline, tetracycline, cloxacillin,
erythromycin, cephalosporin, or clindamycin),
intralesional corticosteroid, and oral prednisolone
(Otberg & Shapiro, 2012). The benefits of systemic
antibiotics were considered to be their anti-
inflammatory effects rather than antibacterial (Otberg
& Shapiro, 2012). Isotretinoin 0,5-1 mg/kg/day has
shown prolonged remission (Otberg & Shapiro,
2012). The mechanisms of action of isotretinoin are
normalizing follicular keratinization and reducing the
aberrant immune responses (Scheinfeld, 2014). Anti-
TNF α may be used when isotretinoin fails
(Scheinfeld, 2014). It can also defer the need of a
surgical treatment (Scheinfeld, 2014). Incision and
drainage may be done to painful and resistant nodules
(Scheinfeld, 2014). Marsupialization with curettage
of the cyst wall and total scalp excision followed by
split-thickness skin grafting have been reported, but
these surgical procedures should only be done for
extreme and refractory cases (Otberg & Shapiro,
2012). Badaoui et al. (2016) reported that 78%
patients receiving systemic antibiotics (doxycycline,
pristamycin, rifampicin, or a combination of several
antibiotics) showed moderate improvement.
However, the disease was relapsed in all of those
patients after antibiotic cessation (Badaoui et al.,
2016). Seventy one percent patients had received
systemic retinoid and almost all (92%) showed
complete remission after 3 months (Badaoui et al.,
2016). Isotretinoin is considered as the first line
therapeutic option for DCS (Badaoui et al., 2016;
Fransisco et al., 2017). The efficacy of isotretinoin in
treating DCS has been published (Marquis et al.,
2017). However, the optimal dose, duration of
therapy, and combination with other agents have not
been fully elucidated (Marquis et al., 2017). Marquis
et al.(2017) reported an excellence therapeutic
response after 4 months course of isotretinoin at 0,27
mg/kg/day. Considering the possibility of developing
side effects given at higher dose, this patient received
isotretinoin 20 mg daily (equal to 0,25 mg/kg/day).
He has been receiving isotretinoin for the past two
months and showed improvement.
4 CONCLUSIONS
DCS is a very rare case in Indonesia and should be
recognized as one of differential diagnosis when
seeing nodules, abscesses, and sinuses on the scalp.
The diagnosis can be confirmed by clinical,
trichoscopic, and histopathological examinations.
The therapy can be started immediately after the
diagnosis has been confirmed.